Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nasal-spraying immune influenza multivalent vaccine and preparation method thereof

A technology of influenza vaccine and multivalent vaccine, applied in the field of vaccines, can solve the problems of immune protection without mucosal immune effect, achieve the effect of preventing highly pathogenic human avian influenza, avoiding pain and cross-infection, and simple preparation

Inactive Publication Date: 2009-06-10
MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As far as the influenza vaccine is immunized by injection, the immune response and immune protection caused by it have no local mucosal immune effect, that is, it cannot achieve effective antibody neutralization and cellular immunity when the influenza virus invades.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nasal-spraying immune influenza multivalent vaccine and preparation method thereof
  • Nasal-spraying immune influenza multivalent vaccine and preparation method thereof
  • Nasal-spraying immune influenza multivalent vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1: the preparation of influenza quadrivalent (H1N1, H3N2, H5N1 and B type) attenuated live vaccine strain

[0037] Type A influenza virus strains H1, H3, H5 and type B influenza virus strains were provided by China CDC and Hualan Biotechnology Co., Ltd. Adopt the traditional chicken embryo allantoic cavity culture influenza virus method or microcarrier suspension culture and tame mammalian cells (such as Vero cells, MDCK cells, 2BS cells, etc.) to culture influenza virus.

[0038] ①Using the existing reverse genetics method, the cold-adapted attenuated influenza virus strain A / Ann Arbor / 6 / 60 was used as the virus backbone for type A polyvalent virus, and B / Ann Arbor / 1 / 66 was used as the backbone for type B polyvalent virus. Rescue the virus skeleton, integrate the HA and NA surface antigen genes of the popular influenza A and B strains of the year, and co-transfect lactation with 8, 3 or 4 recombinant plasmids constructed from H1N1, H3N2, H5N1 and B influenza...

Embodiment 2

[0042] Example 2: Preparation of influenza multivalent (H1N1, H3N2, B, H5N1, H7N7, H9N2 subtypes) live attenuated vaccine antigens

[0043] Type A influenza virus strains H1N1, H3N2, H5N1, H7N7, H9N2 subtypes and type B influenza virus strains were provided by China CDC and Hualan Biotechnology Co., Ltd. Adopt the traditional chicken embryo allantoic cavity culture influenza virus method or microcarrier suspension culture and tame mammalian cells (such as Vero cells, MDCK cells, 2BS cells, etc.) to culture influenza virus.

[0044] ①Using the existing reverse genetics method, the antigen of type A multivalent vaccine is based on the cold-adapted attenuated influenza virus strain A / Ann Arbor / 6 / 60 as the virus backbone, and the antigen of type B multivalent vaccine is based on B / Ann Arbor / 1 / 66 In order to save the virus skeleton, integrate the HA and NA surface antigen genes of influenza A and B strains that were popular in the year, and co-transfect mammals with 8, 3 or 4 reco...

Embodiment 3

[0048] Example 3: Observation of the in vivo effect of influenza quadrivalent live attenuated vaccine in mice

[0049] 1. Immunization strategy, using different dosage forms of influenza virus vaccine to immunize mice

[0050] ① According to the method for preparing influenza quadrivalent (H1N1, H3N2, H5N1 and B type) attenuated live virus strains in Example 1, at the same time dilute the antigen with a stabilizer to the amount of the attenuated live vaccine ≥ 5 × 10 6 EID 50 , in which nasal inactivated influenza vaccine + AL(OH) 3 The adjuvant group was the control (Tab1).

[0051] ②The 6 groups of Balb / c mice received nasal immunization with vaccines of different dosage forms, 20 μl of antigen solution per mouse, in which the inactivated influenza vaccine contained AL(OH) 3 adjuvant. Immunization was carried out on the 0th and 28th day respectively, and the IgG, IgA and HAI titers in the serum, nasal washing fluid and lung washing fluid were measured on the 42nd day.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a nasal spray immunity flu polyvalent vaccine and a preparing method. Flu quadrivalence (H1N1, H3N2, H5N1, B type) or polyvalent attenuated live vaccine is used for immunoprophylaxis through nose spraying, popular flu and highly pathogenic avian influenza can be prevented safely and efficiently.

Description

technical field [0001] The invention relates to a vaccine, in particular to a multivalent influenza vaccine for nasal spray immunization. Background technique [0002] Influenza is an acute febrile respiratory infectious disease caused by influenza virus, which can cause serious complications. The antigens of influenza virus are constantly changing, and they are highly contagious, often causing large-scale epidemics. In a normal epidemic season, about 10% of the world's population, or more than 500 million people, suffer from influenza. At present, no ideal prevention and treatment drugs have been found. Influenza vaccination is still an effective means of preventing influenza today. Influenza vaccination of healthy people will prevent the disease in 70-90% of the people (when the circulating virus strain is the same as the vaccine strain), and more importantly, vaccination of high-risk groups can significantly reduce the incidence of influenza. occurrence, reducing hospit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/295A61K39/145A61K47/42A61K9/72A61K9/12A61K9/14A61K9/16A61K45/06A61P31/16
Inventor 杨鹏辉王希良罗德炎段跃强邢丽王金成
Owner MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products